Sponsor

Institute for Neurodegenerative Disorders

Clinical research sponsor

Published trials50
Recruiting shown4
Roles2
SourceClinicalTrials.gov

Clinical trials

50 shown
Study to Evaluate the Feasibility of [18F]Florbetapir PET for Assessment in MS PatientsNCT01767493 · lead sponsor · 2012-11-01
COMPLETED
Evaluation of [18F]MPPF as a Brain Tracer of Serotonin Receptor 5HT1aNCT01461083 · lead sponsor · 2011-09-01
COMPLETED
Research Involving Subjects With Parkinson's Disease, Alzheimer Disease and Healthy ControlsNCT01461109 · lead sponsor · 2011-08-01
COMPLETED
Evaluation of [18F]MK-9470 as a Brain Tracer of Cannabinoid-1 Receptor in Parkinson's Disease and Healthy SubjectsNCT01462708 · lead sponsor · 2011-05-01
COMPLETED
Evaluation of [18F] FMH3 and PET as a Marker of Histamine-3 Receptor Activity in Subjects With AD Compared w/ HCNCT01268020 · lead sponsor · 2010-12-01
COMPLETED
Safety and Efficacy of Positron Emission Tomography (PET) Imaging With MNI-558NCT01217021 · lead sponsor · 2010-09-01
COMPLETED
Evaluation of [18F] PBR111 and PET as a Marker of Inflammation in Subjects With Neurological ConditionsNCT01209156 · lead sponsor · 2010-03-01
COMPLETED
Evaluation of [18F] PBR06 and PET as a Marker of Inflammation in Subjects With Neurological ConditionsNCT01028209 · lead sponsor · 2009-11-01
TERMINATED
Safety and Efficacy of Positron Emission Tomography Imaging With MNI-513NCT01000870 · lead sponsor · 2009-10-01
TERMINATED
Evaluation of [18F] FEPPA and PET Imaging as a Marker of Inflammation in Subjects With Neurological ConditionsNCT00970333 · lead sponsor · 2009-08-01
COMPLETED
Evaluation of [123I]MNI-420 and SPECT as a Marker of the Adenosine A2a Receptor in PD, HD and Healthy Subjects.NCT00970229 · lead sponsor · 2009-07-01
COMPLETED
Single Photon Emission Computed Tomography (SPECT) Imaging Study to Develop a Biomarker for Alzheimer's DiseaseNCT00886951 · lead sponsor · 2009-03-01
TERMINATED
A PET Brain Imaging Study of mGluR5 in Subjects With Neuropsychiatric ConditionsNCT00870974 · lead sponsor · 2009-03-01
COMPLETED
Brain Imaging Study in Subjects With Alzheimer Disease in Comparison to Healthy SubjectsNCT00870519 · lead sponsor · 2009-01-01
TERMINATED
Evaluation of [123I] MNI-340 and SPECT as a Marker of Beta-Amyloid Protein DepositionNCT00968097 · lead sponsor · 2008-04-01
TERMINATED
Evaluation of [123I] MNI-330 and SPECT as a Marker of Beta-amyloid Protein DepositionNCT00657813 · lead sponsor · 2008-03-01
TERMINATED
Evaluation of [123I]CLINDE and SPECT as a Marker of Inflammation in Subjects With PD or AD and in Healthy SubjectsNCT00612872 · lead sponsor · 2008-01-01
TERMINATED
Evaluation of [123I] AV51 and SPECT as a Marker of Beta-amyloid Protein Deposition in Subjects With Alzheimer Disease in Comparison to Healthy SubjectsNCT00556660 · lead sponsor · 2007-09-01
COMPLETED
Evaluation of [123I] AV94 and SPECT in Subjects With Alzheimer Disease in Comparison to Healthy SubjectsNCT00605059 · lead sponsor · 2007-08-01
TERMINATED
Evaluation of [123I] AV151 and SPECT in Subjects w/ AD in Comparison to Healthy SubjectsNCT00605046 · lead sponsor · 2007-08-01
TERMINATED
Development of Cognitive Assessment Tools in Parkinson DiseaseNCT00556764 · lead sponsor · 2007-07-01
COMPLETED
Evaluation of [123I] MNI-187 and SPECT in Patients With Alzheimers Disease in Comparison to Healthy SubjectsNCT00456417 · lead sponsor · 2007-04-01
COMPLETED
Evaluation of 123-I Iodobenzovesamicol (IBVM) and SPECT Imaging of Healthy Subjects and Patients With Alzheimer DiseaseNCT00480701 · lead sponsor · 2007-02-01
COMPLETED
Assessment of the Biodistribution and Safety of 123-I MZINT in Healthy Subjects and Parkinson Disease PatientsNCT00427674 · lead sponsor · 2007-01-01
TERMINATED
Assessing Imaging as a Tool in Monitoring and Predicting the Progression of Parkinson DiseaseNCT00404170 · lead sponsor · 2006-11-01
COMPLETED
A Study Evaluating Potential Screening Tools for Detecting Parkinson DiseaseNCT00387075 · lead sponsor · 2006-11-01
UNKNOWN
Evaluation of 5-[123I]-A-85380 and SPECT Imaging in Individuals With Parkinsons DiseaseNCT00397696 · lead sponsor · 2006-11-01
COMPLETED
The Study of the Impact of Disclosing Imaging Study Information to Trial ParticipantsNCT00354003 · lead sponsor · 2006-07-01
COMPLETED
Assess 123-I IMPY and SPECT Imaging as a Tool to Detect β-Amyloid in the BrainNCT00287248 · lead sponsor · 2006-02-01
COMPLETED
Development of Imaging, Clinical and Biochemical Bio-Markers for Parkinson's DiseaseNCT00315250 · lead sponsor · 2006-01-01
COMPLETED
Imaging and Genetic Biomarkers of Parkinson Disease (PD) Onset and Progression in High-risk FamiliesNCT00273351 · lead sponsor · 2006-01-01
COMPLETED
Study of the Effects of Dopaminergic Medications on Dopamine Transporter Density in Subjects With Parkinson's DiseaseNCT00129181 · lead sponsor · 2005-01-01
COMPLETED
A Study of the Sense of Smell in Relatives of Parkinson's Disease PatientsNCT00096876 · lead sponsor · 2004-10-01
COMPLETED
Study of the Effects of Dopaminergic Medications on Dopamine Transporter Imaging in Parkinson's DiseaseNCT00096720 · lead sponsor · 2004-02-01
COMPLETED
A Study of Neurophysiologic Changes in Individuals With Parkinson's DiseaseNCT00117195 · lead sponsor · 2003-05-01
COMPLETED
Study of Individuals With Parkinson's Symptoms But in Whom There is Diagnostic UncertaintyNCT00129675 · lead sponsor · 2003-02-01
COMPLETED
A Study of Brain Imaging With Nuclear Medicine Technology in Individuals With and at Risk for Parkinson's DiseaseNCT00117819 · lead sponsor · 2001-03-01
COMPLETED
Long-Term Dopamine Transporter Imaging and Clinical Assessment of Parkinson's Disease ProgressionNCT00134784 · lead sponsor · 2000-04-01
COMPLETED
Study of Brain Imaging With Nuclear Technology in Individuals With Parkinsonian SyndromeNCT00132626 · lead sponsor · 1992-09-01
COMPLETED
Evaluation of the Pharmacokinetics, Biodistribution and Radiation Dosimetry of [18F]MODAG-009 Positron Emission Tomography (PET) Radiotracers in Adult Healthy VolunteersNCT07617688 · collaborator · 2026-05-27
RECRUITING
Evaluation of [¹⁸F]MODAG-009 PET Imaging in SynucleinopathiesNCT07640555 · collaborator · 2026-05-13
RECRUITING
Evaluation of Tau-Pathology in Sporadic and LRRK2 Parkinson's DiseaseNCT07020026 · collaborator · 2025-05-12
RECRUITING
PPMI Clinical - Establishing a Deeply Phenotyped PD CohortNCT04477785 · collaborator · 2020-07-01
RECRUITING
PPMI Tau PET ImagingNCT04906590 · collaborator · 2021-08-30
COMPLETED
Quantitative Evaluation of [18F]T807 as a Potential PET Radioligand for Imaging Tau in Patients With Alzheimer's DiseaseNCT02370524 · collaborator · 2015-01-01
COMPLETED
Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Tauopathies Compared to Healthy SubjectsNCT02103894 · collaborator · 2014-02-01
COMPLETED
Study to Identify Clinical, Imaging and Biologic Markers of Parkinson Disease ProgressionNCT01141023 · collaborator · 2010-06-01
COMPLETED
Evaluation of [123I] AV83 and SPECT in Patients With Alzheimer Disease in Comparison to Healthy ControlsNCT00448799 · collaborator · 2007-03-01
COMPLETED
Use of [123I] AV39 and SPECT Imaging as a Marker of Protein Disposition in Subjects With Alzheimer Disease Compared to Healthy SubjectsNCT00439010 · collaborator · 2007-02-01
COMPLETED
ALTROPANE® SPECT Imaging in Patients With Parkinson DiseaseNCT00397228 · collaborator · 2006-11-01
COMPLETED

Sponsor roles

lead sponsor39
collaborator11

How to interpret this record

CureCurrent links normalized diseases, medicines, registry study labels, sponsors and research sites. A link is not the same as a finding of clinical effectiveness. Our research guides explain how to compare studies, decode RxNorm identities, and avoid over-interpreting site and trial counts. See the published database coverage for mapping completeness.

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.